Ribociclib FDA label updated to include pre- and perimenopausal women©United States Food and Drug Agency

FDA approved avatrombopag for thrombocytopenia in CLD patients scheduled for a procedure

/1 Comment/in /by

 

You might also like
Pembrolizumab plus axitinib FDA approved for the first-line treatment of advanced renal cell carcinoma patients
FDA approved nilotinib for paediatric patients with newly diagnosed Ph+ CML-CP or Ph+ CML-CP resistant or intolerant to prior TKI
Ribociclib FDA label updated to include pre- and perimenopausal women©United States Food and Drug Agency FDA approved pembrolizumab for 3rd-line PMBCL in adult and pediatric patients
FDA approved lusutrombopag (Mulpleta, Shionogi Inc.) for thrombocytopenia in adults with chronic liver disease who are scheduled to undergo a medical or dental procedure. More Information.  July 31, 2018. FDA approved mogamulizumab for adult patients with relapsed or refractory CTCL
Pembrolizumab FDA approved for adjuvant treatment of melanoma
Calaspargase pegol-mknl (Asparlas®) FDA approved in paediatric and young adult acute lymphoblastic leukaemia (ALL) patients
Single-agent pembrolizumab FDA approved for the first-line treatment of stage III NSCLC with PD-L1 TPS ≥1%
Pembrolizumab plus pemetrexed-platinum approved for use in the 1st-line treatment of metastatic non-squamous NSCLC Pembrolizumab plus pemetrexed-platinum FDA approved for first-line treatment of metastatic non-squamous NSCLC
1 reply

Trackbacks & Pingbacks

  1. FDA approved avatrombopag for thrombocytopenia in CLD patient scheduled for a procedure - MediNews Asia says:
    23rd May 2018 at 11:47 PM

    […] post FDA approved avatrombopag for thrombocytopenia in CLD patient scheduled for a procedure appeared first on Medical Writer Agency | 香港醫學作家 | MediPR | MediPaper Hong […]

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply